What amount sold does Bioceptive, Inc. report in Form D filings?

The latest linked filings report $2.9M sold across 5 identified offering(s). 0 unlinked amendment(s) are excluded; 0 offering(s) have no reported amount sold. This is not verified lifetime funding or money raised during a specific period.

When was Bioceptive, Inc.'s most recent SEC filing?

Bioceptive, Inc.'s most recent Form D filing was on 2016-01-29.

How many investors does Bioceptive, Inc. have?

The most recent Form D filing lists 16 investor(s).

What type of securities does Bioceptive, Inc. offer?

Bioceptive, Inc.'s SEC Form D filings indicate equity offerings.

Bioceptive, Inc.

CIK: 0001527900·Biotechnology·NEW ORLEANS, LA·Corporation·Founded 2011

Reported Sold

$2,905,060

Total Filings

Identified Offerings

Last Filed

Jan 29, 2016

Employees

—

Reported sold uses the latest linked filing for each identified offering; it is not verified lifetime funding. SPV filings are shown separately.

About

Company in Biotechnology industry

SEC EDGAR

Offering filing timeline

Jan 29, 2016Form D — New notice

Reported sold: $416,450 · Target: $650,000

Rule 506(b)·16 investors

Dec 30, 2013Form D — New notice

Reported sold: $1,250,000 · Target: $1,500,000

Rule 506(b)·12 investors

Mar 1, 2013Form D/A — Amendment

Reported sold: $1,063,610 · Target: $1,100,000

Rule 506·0 investors

Changed: Reported amount sold, Offering target

Oct 24, 2012Form D — New notice

Reported sold: $0 · Target: $1,000,000

Rule 506·0 investors

Mar 26, 2012Form D — New notice

Reported sold: $40,000 · Target: $200,000

Rule 506·2 investors

Mar 26, 2012Form D/A — Amendment

Reported sold: $40,000 · Target: $250,000

Rule 506·2 investors

Changed: Offering target

Aug 15, 2011Form D — New notice

Reported sold: $135,000 · Target: $135,000

Rule 506·3 investors

Fundraising Profile

Exemptions

Rule 506(b)

Investors in latest filing

Revenue Range

Decline to Disclose

Reported commissions across identified offerings

Amendment Rate

29%

Latest reported sold across 5 identified offerings

$2,905,060

Uses the latest linked filing for each offering. This is not a measure of money raised in the last year or verified lifetime funding.

Key People

Benjamin Cappiello

Related Person

Appears on 5 filings

John Hardman

Related Person

Appears on 3 filings

Joan Neuscheler

Related Person

Appears on 2 filings

Stewart Davis

Related Person

Appears on 2 filings

Shuchi Khurana

Related Person

Appears on 2 filings

Orin Levy

Related Person

Appears on 2 filings

Stewart Davis

Related Person

Appears on 1 filing

Stewart Davis

Related Person

Appears on 1 filing

Filing History

Date	Type	Offering target	Reported sold	Investors
Jan 29, 2016	New	$650,000	$416,450	16
Dec 30, 2013	New	$1,500,000	$1,250,000	12
Mar 1, 2013	Amendment	$1,100,000	$1,063,610	0
Oct 24, 2012	New	$1,000,000	$0	0
Mar 26, 2012	Amendment	$250,000	$40,000	2
Mar 26, 2012	New	$200,000	$40,000	2
Aug 15, 2011	New	$135,000	$135,000	3

Filing History

Amendment insights

Loading amendment history…

Comparable issuers

Matched on reported industry and issuer type, then ranked by business location, offering target, and recency. These are filing comparables, not verified business competitors.

28bio, Inc.

Biotechnology

Offering target: $8,524,945

Filed Oct 29, 2026